Teva Claims Diovan 180-Day Exclusivity, Arguing Ranbaxy ANDA Was Incomplete
This article was originally published in PharmAsia News
Executive Summary
Teva supports citizen petition claiming Ranbaxy is ineligible for exclusivity but says that it is the actual first ANDA filer; generic has yet to launch nearly two years after Novartis’ Diovan patents expired.